Kara Rice

536 total citations
16 papers, 309 citations indexed

About

Kara Rice is a scholar working on Immunology, Nephrology and Hematology. According to data from OpenAlex, Kara Rice has authored 16 papers receiving a total of 309 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 7 papers in Nephrology and 5 papers in Hematology. Recurrent topics in Kara Rice's work include Renal Diseases and Glomerulopathies (7 papers), Platelet Disorders and Treatments (4 papers) and Complement system in diseases (4 papers). Kara Rice is often cited by papers focused on Renal Diseases and Glomerulopathies (7 papers), Platelet Disorders and Treatments (4 papers) and Complement system in diseases (4 papers). Kara Rice collaborates with scholars based in United States, United Kingdom and Spain. Kara Rice's co-authors include Craig C Benson, Stacey Poloskey, David M. Pariser, Janice M. Staber, Amy D. Shapiro, David H. Collier, Doris Quon, Dan Rudin, Joachim Fruebis and Barbara A. Konkle and has published in prestigious journals such as New England Journal of Medicine, Blood and Neurology.

In The Last Decade

Kara Rice

15 papers receiving 300 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kara Rice United States 8 189 145 72 40 33 16 309
Miriam Teoli Italy 11 91 0.5× 244 1.7× 124 1.7× 34 0.8× 16 0.5× 22 384
Chantana Polprasert Thailand 9 89 0.5× 77 0.5× 31 0.4× 26 0.7× 45 1.4× 42 226
Tania Gudu Romania 7 136 0.7× 173 1.2× 30 0.4× 15 0.4× 15 0.5× 26 317
Yakai Fu China 8 46 0.2× 52 0.4× 26 0.4× 62 1.6× 25 0.8× 17 248
Richard J. Buka United Kingdom 7 178 0.9× 67 0.5× 49 0.7× 66 1.6× 29 0.9× 19 379
Ole Maywald Germany 7 142 0.8× 25 0.2× 5 0.1× 32 0.8× 89 2.7× 11 209
Rie Suematsu Japan 11 176 0.9× 248 1.7× 14 0.2× 69 1.7× 8 0.2× 18 343
Maura Couto Portugal 7 27 0.1× 145 1.0× 11 0.2× 18 0.5× 12 0.4× 20 230
María Laura Acosta Felquer Argentina 10 166 0.9× 263 1.8× 36 0.5× 11 0.3× 3 0.1× 15 387
M-C Béné France 5 152 0.8× 34 0.2× 5 0.1× 36 0.9× 27 0.8× 9 223

Countries citing papers authored by Kara Rice

Since Specialization
Citations

This map shows the geographic impact of Kara Rice's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kara Rice with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kara Rice more than expected).

Fields of papers citing papers by Kara Rice

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kara Rice. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kara Rice. The network helps show where Kara Rice may publish in the future.

Co-authorship network of co-authors of Kara Rice

This figure shows the co-authorship network connecting the top 25 collaborators of Kara Rice. A scholar is included among the top collaborators of Kara Rice based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kara Rice. Kara Rice is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Lafayette, Richard, Roberta Fenoglio, Jessica Kaufeld, et al.. (2024). Efficacy and Safety of Ravulizumab in IgA Nephropathy. Journal of the American Society of Nephrology. 36(4). 645–656. 13 indexed citations
2.
Tumlin, James A., Jonathan Barratt, Mai-Szu Wu, et al.. (2024). Efficacy and Safety of Ravulizumab in IgAN: Week 50 Results from a Phase 2 Randomized Controlled Trial. Journal of the American Society of Nephrology. 35(10S).
3.
Trimarchi, Hernán, Jonathan Barratt, Hiddo J.L. Heerspink, et al.. (2024). #1021 A phase 3 randomized controlled trial of ravulizumab in adult patients with IgA nephropathy. Nephrology Dialysis Transplantation. 39(Supplement_1). 2 indexed citations
4.
Barratt, Jonathan, Miguel Ángel Pérez Valdivia, Dario Roccatello, et al.. (2024). WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY. Kidney International Reports. 9(4). S155–S156. 1 indexed citations
5.
Valdivia, Miguel Ángel Pérez, James A. Tumlin, Jessica Kaufeld, et al.. (2024). #145 Subgroup and secondary endpoint evaluation of a phase 2 randomized placebo-controlled trial of ravulizumab in IgA nephropathy. Nephrology Dialysis Transplantation. 39(Supplement_1). 2 indexed citations
6.
Barratt, Jonathan, et al.. (2023). Efficacy and Safety of Ravulizumab in a Phase 2 Randomized Controlled Trial in IgA Nephropathy. Journal of the American Society of Nephrology. 34(11S). B8–B8. 2 indexed citations
7.
8.
Podos, Steven D., Howard Trachtman, Gerald B. Appel, et al.. (2022). Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan. American Journal of Nephrology. 53(10). 675–686. 11 indexed citations
9.
10.
Willemze, Annemieke, et al.. (2021). Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Advances. 6(4). 1089–1094. 29 indexed citations
11.
Konkle, Barbara A., Amy D. Shapiro, Doris Quon, et al.. (2020). BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. New England Journal of Medicine. 383(11). 1018–1027. 95 indexed citations
12.
13.
Konkle, Barbara A., Amy D. Shapiro, Doris Quon, et al.. (2018). BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer. Blood. 132(Supplement 1). 636–636. 13 indexed citations
14.
Bagel, Jerry, Stephen K. Tyring, Kara Rice, et al.. (2017). Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab. British Journal of Dermatology. 177(2). 411–418. 7 indexed citations
15.
Paller, Amy S., Elaine C. Siegfried, David M. Pariser, et al.. (2016). Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. Journal of the American Academy of Dermatology. 74(2). 280–287.e3. 73 indexed citations
16.
Kimball, Alexa B., Kenneth J. Rothman, Gregory Kricorian, et al.. (2014). OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. Journal of the American Academy of Dermatology. 72(1). 115–122. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miriam Teoli Breakdown of academic impact, for papers by Chantana Polprasert Breakdown of academic impact, for papers by Tania Gudu Breakdown of academic impact, for papers by Yakai Fu Breakdown of academic impact, for papers by Richard J. Buka Breakdown of academic impact, for papers by Ole Maywald Breakdown of academic impact, for papers by Rie Suematsu Breakdown of academic impact, for papers by Maura Couto Breakdown of academic impact, for papers by María Laura Acosta Felquer Breakdown of academic impact, for papers by M-C Béné
Rankless by CCL
2026